# Poly Medicure (NSE: POLYMED) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/POLYMED · Pivot · prices to 22 Oct 2026

Poly Medicure (NSE: POLYMED) closed at ₹1,479.10 on 22 Oct 2026, up 1.31% on the day. With a market capitalisation of ₹14,992 Cr, it ranks 423rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.

At its last close the stock traded at 46.7× trailing earnings, against a return on equity of 10.4% in FY26. Over the past year the share price has fallen 20.5%. Its 52-week range is ₹1,182.00 (30 Mar 2026) to ₹2,094.30 (11 Nov 2025); the last close is 29.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹535 Cr (+21.3% year on year) and net profit ₹63 Cr (−29.3%), on a consolidated basis. Promoters held 62.42% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,479.10 |
| Market cap | ₹14,992 Cr |
| P/E (trailing) | 46.7 |
| ROE | 10.4% (FY26) |
| ROCE | 13.4% (FY26) |
| Debt to equity | 0.11 |
| 52-week high | ₹2,094.30 (11 Nov 2025) |
| 52-week low | ₹1,182.00 (30 Mar 2026) |
| 1-year return | −20.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹535 Cr | +21.3% | ₹63 Cr | −29.3% | ₹6.54 |
| Q3 FY26 | ₹494 Cr | +16.4% | ₹69 Cr | −17.2% | ₹7.00 |
| Q2 FY26 | ₹444 Cr | +5.7% | ₹91 Cr | +3.9% | ₹9.06 |
| Q1 FY26 | ₹403 Cr | +4.8% | ₹92 Cr | +23.9% | ₹9.19 |
| Q4 FY25 | ₹441 Cr | +16.6% | ₹90 Cr | +31.0% | ₹8.92 |
| Q3 FY25 | ₹424 Cr | +24.9% | ₹84 Cr | +28.4% | ₹8.48 |
| Q2 FY25 | ₹420 Cr | +24.5% | ₹87 Cr | +40.6% | ₹9.01 |
| Q1 FY25 | ₹385 Cr | +19.9% | ₹74 Cr | +18.1% | ₹7.71 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,670 Cr | ₹333 Cr |
| FY24 | ₹1,376 Cr | ₹256 Cr |
| FY23 | ₹1,115 Cr | ₹177 Cr |
| FY22 | ₹923 Cr | ₹144 Cr |
| FY21 | ₹786 Cr | ₹133 Cr |
| FY20 | ₹687 Cr | ₹94 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 62.42%
- Foreign institutions: 5.57%
- Domestic institutions: 16.08%
- Non-institutions: 15.94%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,272.00 | ₹15,612 Cr | 27.7 | 17.2% |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,430 Cr | 22.9 | 11.2% |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,056.00 | ₹15,140 Cr | 80.9 | 15.0% |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹370.75 | ₹14,966 Cr | 47 | 6.5% |
| [Jubilant Pharmova](https://app.pivotnow.in/stock/JUBLPHARMA) | ₹930.80 | ₹14,826 Cr | 37.1 | 13.4% |
| [Dr. Agarwal's Health Care](https://app.pivotnow.in/stock/AGARWALEYE) | ₹459.10 | ₹14,553 Cr | 100 | 6.6% |

## Questions and answers

### What is the share price of Poly Medicure today?

Poly Medicure (NSE: POLYMED) last closed at ₹1,479.10 on 22 Oct 2026. Its 52-week high is ₹2,094.30 and its 52-week low is ₹1,182.00.

### What is the market cap of Poly Medicure?

Poly Medicure's market capitalisation is ₹14,992 Cr (₹14,992 Cr) at the 22 Oct 2026 close, ranking 423rd among the NSE companies Pivot tracks.

### What is the P/E ratio of Poly Medicure?

Poly Medicure trades at a trailing P/E of 46.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 47.

### What is the ROE and ROCE of Poly Medicure?

Return on equity was 10.4% in FY26 and return on capital employed was 13.4% in FY26 (consolidated figures).

### Is Poly Medicure a debt-free company?

No. Poly Medicure's debt-to-equity ratio was 0.11 in FY26, with total debt of ₹52 Cr.

### What were Poly Medicure's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Poly Medicure reported revenue of ₹535 Cr, +21.3% year on year, and net profit of ₹63 Cr, −29.3% year on year.

### How has Poly Medicure stock performed over the last year?

Poly Medicure's share price has fallen 20.5% over the past year, −11.2% over three months and −13.9% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Poly Medicure?

As of 30 Jun 2026: promoters 62.42%, foreign institutions 5.57%, domestic institutions 16.08%, non-institutions 15.94%.

### Who are Poly Medicure's competitors?

The listed Pharma & Healthcare companies closest to Poly Medicure by market cap are Alivus Life Sciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Syngene International, Jubilant Pharmova and Dr. Agarwal's Health Care.

### Is Poly Medicure a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Poly Medicure's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on POLYMED against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.